Literature DB >> 26833684

The genomic landscape of cutaneous melanoma.

Tongwu Zhang1, Ken Dutton-Regester2,3,4, Kevin M Brown1, Nicholas K Hayward4.   

Abstract

Somatic mutation analysis of melanoma has been performed at the single gene level extensively over the past several decades. This has provided considerable insight into the critical pathways controlling melanoma initiation and progression. During the last 5 yr, next-generation sequencing (NGS) has enabled even more comprehensive mutational screening at the level of multigene panels, exomes and genomes. These studies have uncovered many new and unexpected players in melanoma development. The recent landmark study from The Cancer Genome Atlas (TCGA) consortium describing the genomic architecture of 333 cutaneous melanomas provides the largest and broadest analysis to date on the somatic aberrations underlying melanoma genesis. It thus seems timely to review the mutational landscape of melanoma and highlight the key genes and cellular pathways that appear to drive this cancer.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  driver gene; exome sequencing; genomics; melanoma; mutation; ultraviolet radiation

Mesh:

Year:  2016        PMID: 26833684     DOI: 10.1111/pcmr.12459

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  52 in total

1.  cAMP-independent non-pigmentary actions of variant melanocortin 1 receptor: AKT-mediated activation of protective responses to oxidative DNA damage.

Authors:  María Castejón-Griñán; Cecilia Herraiz; Conchi Olivares; Celia Jiménez-Cervantes; Jose Carlos García-Borrón
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

2.  Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.

Authors:  Bradley Garman; Ioannis N Anastopoulos; Clemens Krepler; Patricia Brafford; Katrin Sproesser; Yuchao Jiang; Bradley Wubbenhorst; Ravi Amaravadi; Joseph Bennett; Marilda Beqiri; David Elder; Keith T Flaherty; Dennie T Frederick; Tara C Gangadhar; Michael Guarino; David Hoon; Giorgos Karakousis; Qin Liu; Nandita Mitra; Nicholas J Petrelli; Lynn Schuchter; Batool Shannan; Carol L Shields; Jennifer Wargo; Brandon Wenz; Melissa A Wilson; Min Xiao; Wei Xu; Xaiowei Xu; Xiangfan Yin; Nancy R Zhang; Michael A Davies; Meenhard Herlyn; Katherine L Nathanson
Journal:  Cell Rep       Date:  2017-11-14       Impact factor: 9.423

Review 3.  What makes oncogenes mutually exclusive?

Authors:  Jaroslaw Cisowski; Martin O Bergo
Journal:  Small GTPases       Date:  2016-07-14

Review 4.  Roles of UVA radiation and DNA damage responses in melanoma pathogenesis.

Authors:  Aiman Q Khan; Jeffrey B Travers; Michael G Kemp
Journal:  Environ Mol Mutagen       Date:  2018-02-21       Impact factor: 3.216

5.  Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Authors:  V Gopalakrishnan; C N Spencer; L Nezi; A Reuben; M C Andrews; T V Karpinets; P A Prieto; D Vicente; K Hoffman; S C Wei; A P Cogdill; L Zhao; C W Hudgens; D S Hutchinson; T Manzo; M Petaccia de Macedo; T Cotechini; T Kumar; W S Chen; S M Reddy; R Szczepaniak Sloane; J Galloway-Pena; H Jiang; P L Chen; E J Shpall; K Rezvani; A M Alousi; R F Chemaly; S Shelburne; L M Vence; P C Okhuysen; V B Jensen; A G Swennes; F McAllister; E Marcelo Riquelme Sanchez; Y Zhang; E Le Chatelier; L Zitvogel; N Pons; J L Austin-Breneman; L E Haydu; E M Burton; J M Gardner; E Sirmans; J Hu; A J Lazar; T Tsujikawa; A Diab; H Tawbi; I C Glitza; W J Hwu; S P Patel; S E Woodman; R N Amaria; M A Davies; J E Gershenwald; P Hwu; J E Lee; J Zhang; L M Coussens; Z A Cooper; P A Futreal; C R Daniel; N J Ajami; J F Petrosino; M T Tetzlaff; P Sharma; J P Allison; R R Jenq; J A Wargo
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

Review 6.  Genetically engineered mouse models of melanoma.

Authors:  Eva Pérez-Guijarro; Chi-Ping Day; Glenn Merlino; M Raza Zaidi
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

7.  Fine-tuning AKT kinase activity through direct lysine methylation.

Authors:  Jianping Guo; Wenyi Wei
Journal:  Cell Cycle       Date:  2019-05-03       Impact factor: 4.534

8.  Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.

Authors:  Richard K Yang; Igor B Kuznetsov; Javed Khan; Paul M Sondel; Erik A Ranheim; Jun S Wei; Sivasish Sindiri; Berkley E Gryder; Vineela Gangalapudi; Young K Song; Viharkumar Patel; Jacquelyn A Hank; Cindy Zuleger; Amy K Erbe; Zachary S Morris; Renae Quale; KyungMann Kim; Mark R Albertini
Journal:  Clin Cancer Res       Date:  2020-03-09       Impact factor: 12.531

9.  Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma.

Authors:  Marie R Webster; Mitchell E Fane; Gretchen M Alicea; Subhasree Basu; Andrew V Kossenkov; Gloria E Marino; Stephen M Douglass; Amanpreet Kaur; Brett L Ecker; Keerthana Gnanapradeepan; Abibatou Ndoye; Curtis Kugel; Alexander Valiga; Jessica Palmer; Qin Liu; Xiaowei Xu; Jessicamarie Morris; Xiangfan Yin; Hong Wu; Wei Xu; Cathy Zheng; Giorgos C Karakousis; Ravi K Amaravadi; Tara C Mitchell; Filipe V Almeida; Min Xiao; Vito W Rebecca; Ying-Jie Wang; Lynn M Schuchter; Meenhard Herlyn; Maureen E Murphy; Ashani T Weeraratna
Journal:  Mol Cell       Date:  2019-12-11       Impact factor: 17.970

10.  Editor's Highlight: PPARβ/δ and PPARγ Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis.

Authors:  Michael G Borland; Pei-Li Yao; Ellen M Kehres; Christina Lee; Amanda M Pritzlaff; Elizabeth Ola; Ashley L Wagner; Brooke E Shannon; Prajakta P Albrecht; Bokai Zhu; Boo-Hyon Kang; Gavin P Robertson; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicol Sci       Date:  2017-10-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.